JP7512272B2 - Ａｌｋ２抗体及びその使用方法 - Google Patents

Ａｌｋ２抗体及びその使用方法 Download PDF

Info

Publication number
JP7512272B2
JP7512272B2 JP2021521976A JP2021521976A JP7512272B2 JP 7512272 B2 JP7512272 B2 JP 7512272B2 JP 2021521976 A JP2021521976 A JP 2021521976A JP 2021521976 A JP2021521976 A JP 2021521976A JP 7512272 B2 JP7512272 B2 JP 7512272B2
Authority
JP
Japan
Prior art keywords
seq
alk2
binding fragment
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521976A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020086730A5 (https=
JP2022505585A (ja
JP2022505585A5 (https=
Inventor
エス． シーラ、ジャスバー
ラシェイ、ジェニファー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keros Therapeutics Inc
Original Assignee
Keros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keros Therapeutics Inc filed Critical Keros Therapeutics Inc
Publication of JP2022505585A publication Critical patent/JP2022505585A/ja
Publication of JPWO2020086730A5 publication Critical patent/JPWO2020086730A5/ja
Publication of JP2022505585A5 publication Critical patent/JP2022505585A5/ja
Priority to JP2024102779A priority Critical patent/JP2024114820A/ja
Application granted granted Critical
Publication of JP7512272B2 publication Critical patent/JP7512272B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021521976A 2018-10-23 2019-10-23 Ａｌｋ２抗体及びその使用方法 Active JP7512272B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024102779A JP2024114820A (ja) 2018-10-23 2024-06-26 Ａｌｋ２抗体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749463P 2018-10-23 2018-10-23
US62/749,463 2018-10-23
PCT/US2019/057679 WO2020086730A1 (en) 2018-10-23 2019-10-23 Alk2 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024102779A Division JP2024114820A (ja) 2018-10-23 2024-06-26 Ａｌｋ２抗体及びその使用方法

Publications (4)

Publication Number Publication Date
JP2022505585A JP2022505585A (ja) 2022-01-14
JPWO2020086730A5 JPWO2020086730A5 (https=) 2022-10-18
JP2022505585A5 JP2022505585A5 (https=) 2022-10-18
JP7512272B2 true JP7512272B2 (ja) 2024-07-08

Family

ID=70331231

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521976A Active JP7512272B2 (ja) 2018-10-23 2019-10-23 Ａｌｋ２抗体及びその使用方法
JP2024102779A Pending JP2024114820A (ja) 2018-10-23 2024-06-26 Ａｌｋ２抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024102779A Pending JP2024114820A (ja) 2018-10-23 2024-06-26 Ａｌｋ２抗体及びその使用方法

Country Status (10)

Country Link
US (2) US12331124B2 (https=)
EP (1) EP3870613A4 (https=)
JP (2) JP7512272B2 (https=)
KR (1) KR102919834B1 (https=)
CN (2) CN118955715A (https=)
AU (1) AU2019364415A1 (https=)
BR (1) BR112021007660A2 (https=)
CA (1) CA3116900A1 (https=)
IL (1) IL282424A (https=)
WO (1) WO2020086730A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7504880B2 (ja) 2018-10-26 2024-06-24 ケロス セラピューティクス インコーポレイテッド Ａｌｋ２阻害剤の結晶形
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
CN115362175A (zh) * 2020-02-11 2022-11-18 瑞泽恩制药公司 抗acvr1抗体及其用途
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022240948A1 (en) * 2021-05-11 2022-11-17 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies
WO2023081212A1 (en) * 2021-11-02 2023-05-11 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
US20240150474A1 (en) * 2022-10-27 2024-05-09 Regeneron Pharmaceuticals, Inc. Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015152183A1 (ja) 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
WO2016121908A1 (ja) 2015-01-30 2016-08-04 学校法人埼玉医科大学 抗ａｌｋ２抗体
JP2017528476A (ja) 2014-09-12 2017-09-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 進行性骨化性線維異形成症の治療

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501781A (ja) * 2004-06-09 2008-01-24 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド 細胞の選択的アポトーシスのための抗体
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
CN102548617B (zh) 2009-03-30 2017-11-07 阿塞勒隆制药公司 Bmp‑alk3拮抗剂和促进骨生长的用途
US20130089560A1 (en) 2010-03-17 2013-04-11 Oncomed Pharmaceuticals Inc Bone morphogenetic protein receptor binding agents and methods of their use
WO2012065059A2 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Treatment of atherosclerosis with bmp-alk3 antagonists
US10620204B2 (en) * 2015-03-26 2020-04-14 Vanderbilt University Antibody-mediated neutralization of Ebola viruses
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
CN115362175A (zh) 2020-02-11 2022-11-18 瑞泽恩制药公司 抗acvr1抗体及其用途
JP2023530316A (ja) 2020-06-16 2023-07-14 インサイト・コーポレイション 貧血の治療のためのａｌｋ２阻害剤
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022098821A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating lymphopenia
WO2022099166A1 (en) 2020-11-09 2022-05-12 Keros Therapeutics, Inc. Methods of treating cardiovascular-related disease
WO2022240948A1 (en) 2021-05-11 2022-11-17 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015152183A1 (ja) 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
JP2017528476A (ja) 2014-09-12 2017-09-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 進行性骨化性線維異形成症の治療
WO2016121908A1 (ja) 2015-01-30 2016-08-04 学校法人埼玉医科大学 抗ａｌｋ２抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Takenobu Katagiri et al.，Development of blocking monoclonal antibodies against ALK2, which is a type I receptor for BMPs，2017 Annual Meeting of the American Society for Bone and Mineral Research, 2017 Abstracts，2017年，Vol. 32, Issue S1，p.S33, Number 1094

Also Published As

Publication number Publication date
EP3870613A4 (en) 2022-08-03
US20250270333A1 (en) 2025-08-28
JP2024114820A (ja) 2024-08-23
KR102919834B1 (ko) 2026-01-30
CN113366019A (zh) 2021-09-07
CN118955715A (zh) 2024-11-15
CA3116900A1 (en) 2020-04-30
KR20210088591A (ko) 2021-07-14
CN113366019B (zh) 2024-08-27
AU2019364415A1 (en) 2021-05-20
EP3870613A1 (en) 2021-09-01
US12331124B2 (en) 2025-06-17
US20210253720A1 (en) 2021-08-19
BR112021007660A2 (pt) 2021-08-03
IL282424A (en) 2021-06-30
WO2020086730A1 (en) 2020-04-30
JP2022505585A (ja) 2022-01-14

Similar Documents

Publication Publication Date Title
JP7512272B2 (ja) Ａｌｋ２抗体及びその使用方法
JP7757439B2 (ja) アクチビンｉｉｂ型受容体変異体を含むポリペプチドおよび医薬組成物
US12522646B2 (en) Activin receptor type II chimeras and methods of use thereof
US20230372390A1 (en) Methods of treating lymphopenia
US20250270287A1 (en) Activin receptor type ii chimeras and methods of use thereof
US20250282877A1 (en) Methods of using alk2 and alk3 antibodies
US20240228583A1 (en) Activin receptor type ii chimeras and methods of use thereof
CA3153062A1 (en) Treatment of liver disease or disorder comprising actrii receptor antagonists
HK40119616A (zh) Alk2抗体及其使用方法
HK40127518A (zh) 激活素受体iib型变体及其使用方法
EP2355840A2 (en) Chemoattractants inhibitors and the use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240313

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240626